Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15595608 | 0.96 | MGLL (0.53) | MGLLMAPTCA12CA1CA2 | |
| SCHEMBL8457415 | 0.91 | TSHR (0.54) | MGLLMAPTCA12CA1CA2 | |
| SCHEMBL15573936 | 0.87 | TSHR (0.56) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL18570122 | 0.87 | KMT2A (0.51) | CA12CA1CA2CA9ATM | |
| SCHEMBL31500911 | 0.85 | NOTUM (0.48) | MGLLCA12CA1CA2CA9 | |
| SCHEMBL18165162 | 0.84 | MGLL (0.53) | MGLLMAPTCA12CA1CA2 | |
| SCHEMBL17992559 | 0.84 | CA12 (0.46) | MGLLMAPTCA12CA1CA2 | |
| SCHEMBL17992563 | 0.84 | CA12 (0.49) | MGLLMAPTCA12CA1CA2 | |
| SCHEMBL1236245 | 0.84 | CA12 (0.47) | MGLLCA12CA1CA2CA9 | |
| SCHEMBL18152526 | 0.83 | CA12 (0.48) | MGLLCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| US-20040198722-A1 | Collections of compounds | SPIROGEN LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
| EP-1109812-A2 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012508-A2 | PYRROLBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| US-5929120-A | Guainidino, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption | MERCK & CO., INC. (US) | 1999-07-27 | — | — | US | disclosed |
| US-5741796-A | Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption | MERCK & CO., INC. (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0760658-A4 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO INC (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0760658-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO. INC. (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1995032710-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO., INC. (US) | 1995-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198722-A1 | Collections of compounds | CBR3, H1-3, H1-0 | MGLL 4303/4885MAPT 4103/4885CA12 332/4885 |
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | MGLL 4821/4885MAPT 2734/4885CA12 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.